"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management.
Salma ShickhLeslie E OldfieldMarc ClausenChloe MightonAgnes SebastianAlessia CalvoNancy N BaxterLesa DawsonLynette S PenneyWilliam FoulkesMark BasikSophie SunKasmintan A SchraderDean A RegierAly KarsanAaron PollettTrevor J PughRaymond H KimYvonne Bombardnull nullPublished in: The oncologist (2022)
Providers anticipated ctDNA testing will transform early cancer detection for HCS families. However, the contrasting positions on ctDNA's role in the care pathway raise potential practice variations, highlighting a need to develop evidence to support clinical implementation and guidelines to standardize adoption.